ZyVersa Therapeutics Business Summary

ZyVersa Therapeutics, Inc. (ZVSA) is a clinical-stage specialty biopharmaceutical company that operates on a research-and-development business model, currently generating revenue through strategic capital raises, equity financing, and potential future licensing milestones rather than product sales. The company’s primary business segments are organized around two proprietary platforms: the Renal pipeline, led by VAR 200 (a Cholesterol Efflux Mediator) targeting focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease; and the Inflammatory pipeline, centered on IC 100, a monoclonal antibody designed to inhibit the ASC component of multiple inflammasomes. ZyVersa competes directly with firms such as Travere Therapeutics, Akebia Therapeutics, Zevra Therapeutics, and Walden Biosciences, positioning itself as a niche innovator by targeting previously unaddressed pathways like renal lipid accumulation and broad-spectrum inflammasome inhibition. The company was founded by Chairman and CEO Stephen C. Glover, a seasoned industry veteran who previously co-founded Coherus BioSciences and held executive roles at Insmed, Andrx, and Amgen. The executive leadership team includes Chief Financial Officer Peter H. Wolfe, who brings extensive specialty finance experience from Kos Pharmaceuticals, and Chief Medical Officer Dr. Pablo A. Guzman, an interventional cardiologist with a pedigree from The Johns Hopkins Hospital. The management is supported by Chief Commercial Officer Karen Cashmere, who has over 25 years of experience in biopharmaceutical business planning. Notable oversight is provided by a board of directors featuring James Sapirstein (CEO of 8 Prime Biosciences) and Gregory G. Freitag (former CFO of Axogen), with recent institutional backing from Williamsburg Venture Holdings via a $10 million share purchase agreement established in mid-2025.